




SHORLA ONCOLOGY
THE HEART OF INNOVATION

 Shorla Oncology Inc.
245 Main St
2nd Floor
Cambridge
MA 02142
USA

 +1 617-225-4379

 info@shorlaoncology.com

 www.shorlaoncology.com

April 15th, 2024

To Whom It May Concern:

This email is to inform the Attorney General's Office for the State of Vermont that Shorla Oncology has release the following product into the commercial market as of December 18th, 2023:

- 81927-0204-01- JYLAMVO ORAL SOLUTION 1 BOTTLE 60 ML 120 MG


This product is a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

- **Marketing Plan** - Jylamvo is a branded oral liquid formulation of methotrexate for adult patients with rheumatoid and oncologic diseases who have difficulty swallowing pills. It will be marketed as an alternative to compounding, pill splitting and pill crushing. Shorla Oncology will be marketing the product to pharmacists, rheumatologists and oncologists through a virtual sales team.
- **Estimated Volume of Patients** – 29,900
- **Breakthrough Therapy Designation** - No
- **FDA Priority Review** - No
- **Acquisition Price** – N/A

Please contact us with any questions.

Sincerely,

RAYNA SETHI HERMAN MBA
CHIEF COMMERCIAL OFFICER

 Shorla Oncology
245 Main St, 2nd Floor,
Cambridge, MA 02142, USA

 rayna.herman@shorlaoncology.com

 +1 (949) 616 0056

 www.shorlaoncology.com

